Literature DB >> 2477330

Monoclonal antibodies reactive with mucin expressed in breast cancer.

P X Xing1, J J Tjandra, S A Stacker, J G Teh, C H Thompson, P J McLaughlin, I F McKenzie.   

Abstract

Three murine monoclonal antibodies (BC1, BC2 and BC3) were developed against human milk fat globule membrane (HMFGM). By immunoperoxidase staining, it was found that the antigenic determinants had a predominant distribution in breast cancer tissue. In addition, the antibodies reacted preferentially with mucin derived from human milk rather than that derived from the breast cancer cell line ZR75; they also recognized polymorphic high molecular weight components (MW greater than or equal to 230,000) in serum and in human milk fat globule membrane. Thus the antibodies appear to react with a component of the family of mucins found in breast cancer and human milk and it appears likely that at least part of each epitope is protein in nature. Antibodies BC1, BC2 and BC3 recognized related but not identical epitopes, and they appear to be co-expressed on the same molecules as 3E1.2-defined antigen (mammary serum antigen, MSA) which is also a member of the family of breast cancer-related mucin. However, the 3E1.2 epitope is distinct and non-cross-reactive with those described for BC1, BC2 and BC3. The BC2 and BC3 defined epitopes were examined for their value in serum assays. Immunoassay was developed with a combination of two antibodies, using antibody BC3 for antigen capture and antibody BC2 or 3E1.2 for antigen detection and gave reasonable sensitivity (approximately 85%) and specificity (approximately 95%) in such serum tests for breast cancer. In a limited study, these tests appeared to complement the MSA test in the detection of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477330     DOI: 10.1038/icb.1989.29

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  20 in total

1.  Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.

Authors:  P X Xing; K Reynolds; G A Pietersz; I F McKenzie
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

2.  Sialyl-Lewis x and Sialyl-Lewis a are associated with MUC1 in human endometrium.

Authors:  N A Hey; J D Aplin
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides.

Authors:  M S Sandrin; H A Vaughan; P X Xing; I F McKenzie
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

4.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 5.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

6.  Constitutive expression of hZnT4 zinc transporter in human breast epithelial cells.

Authors:  Agnes A Michalczyk; Justin Allen; Rachael C Blomeley; M Leigh Ackland
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

7.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

Authors:  V Karanikas; L A Hwang; J Pearson; C S Ong; V Apostolopoulos; H Vaughan; P X Xing; G Jamieson; G Pietersz; B Tait; R Broadbent; G Thynne; I F McKenzie
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

8.  Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Authors:  Subrata K Ghosh; Masashi Uchida; Byunghee Yoo; Alana W Ross; Sandra J Gendler; Jianlin Gong; Anna Moore; Zdravka Medarova
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

9.  Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Authors:  V Apostolopoulos; G A Pietersz; B E Loveland; M S Sandrin; I F McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

10.  Discrimination between alternatively spliced STP-A and -B isoforms of CD46.

Authors:  P X Xing; S Russell; J Prenzoska; J F McKenzie
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.